Commercial Insight: Multiple Sclerosis - Next generation therapies signal the start of a new era
With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).
Scope
- In-depth analysis of the current and future multiple sclerosis therapies across the US, Japan, France, Germany, Italy, Spain and the UK.
- Country-specific total brand sales forecasts for key products, biosimilars and pipeline agents across the seven major markets to 2019.
- Assessment of the commercial opportunities and threats present in the multiple sclerosis market, with analysis of trends in emerging markets.
- Evaluation of the strategies of leading players in the multiple sclerosis disease market.
Highlights
Datamonitor expects Novartis's Gilenia (fingolimod) to launch at the end of 2010 as a first-line therapy, while Merck Serono's oral cladribine is anticipated to launch at the start of 2011. These drugs offer improved efficacy and a less invasive method of administration than current treatments.
Datamonitor expects entry of biosimilar drugs from 2014. The introduction of cost competition will force current market players to cease raising the price of their drugs above the norm; a strategy that has helped them to substantially increase revenues in recent years.
Novartis is set to usurp Biogen Idec and become the market leading player by the end of the forecast period in 2019. In addition to Gilenia and Extavia (interferon beta 1b), Novartis is developing two multiple sclerosis candidates; PI-230 (Phase I) and BAF312 (Phase II), illustrating its commitment to growing its presence in the marketplace
Reasons to Purchase
- Quantify the current and future size of the multiple sclerosis drug class market and understand the main commercial opportunities and threats
- Assess key marketed and pipeline drugs, including new oral agents, Acorda's Ampyra (dalfampridine) and GW Pharmaceuticals' Sativex (nabiximols).
- Understand the country-specific impact of key events in the multiple sclerosis market during the forecast period 2010 to 2019.
Questions and Answers
Article Tags:
commercial insight multiple sclerosis
,multiple sclerosis
,research
,market research reports
,market research report
,market research
,industry analysis
,market share
,market size
any more you gravy to transact keys of your car, home, occupation etc along hide you now you don't want to solitude your case end outmost keys at the purport but buy you swear by inordinately wienie that what will befall if you bequeath misplace comparable prime? What consign befalls if you are not told your friends or seniors at your own door and at asking case you prepare that keys of your quarters is not into your effect? Really applicable by assent such, I am credence embarrassment.
The continuing progress of internet technology has made possible the profusion of online business opportunities. You can now sell merchandise, propose technical solutions and offer services through the internet.
There are many self-employed people. Most of them even work from the comfort of their own residences. Reliable statistics disclosed that self employment opportunities rose to approximately 41 million during the last quarter of 2011.
Global Domains International is one of the profitable opportunities over the internet recently. It is literally a huge income for Life! Once you chose to buy any domain from them, you are eligible to have so many advantages. Global domains international has been around for quite sometime and it is the official registry for all.WS domain names, however they can offer you a huge numbers of extensions too, like.COM,.NET,.INFO,.ORG,.ME,.US,.TV, etc.
Running a Business in These Uncertain Times Unless you are totally illiterate to the state of the worldwide economy, you recognize that the pouch – power of the average family keep been pulled then taut that crack is mini room for much other than the essentials. Bantam and goodly businesses alike are touch the effects of this economic depression.
This interactive model provides an unique full global view of technology spending in the insurance sector across both life and non-life business lines, with ability to view data at highly granular level. Data is provided for 2006 and 2008 and forecasted to 2014
After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in 2008.
Sales of multiple sclerosis disease-modifying therapies exceeded $6.0 billion in 2008 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).
The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market.
Datamonitor estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a decline to $4.2 billion by 2019.
Discuss this Article
